Ace Therapeutics, a specialized contract research organization (CRO) focused on translational blood disorder research, has announced the launch of a comprehensive suite of integrated preclinical hematology CRO services. These services are designed to accelerate the discovery and regulatory advancement of novel therapeutics for a broad spectrum of hematologic diseases, including inherited anemias, autoimmune blood conditions, coagulation defects, myelodysplastic syndromes, and hematopoietic failure disorders.
The company addresses common bottlenecks in preclinical research, such as limited model translatability and fragmented study execution. By offering vertically integrated services, Ace Therapeutics unifies in vitro modeling, in vivo efficacy testing, biomarker profiling, PK/PD analysis, safety toxicology, and custom biospecimen analytics under a single scientific framework. This approach supports developers of gene therapies, biologics, small molecules, RNA modalities, and cell-based treatments.
Central to the offering is a robust collection of in vivo hematologic disease models built across multiple preclinical species, including mice, rats, dogs, and non-human primates. The model bank encompasses genetically engineered lines, chemically induced disease platforms, antibody-triggered autoimmune systems, and patient-derived xenograft (PDX) constructs. For genetic hematological disorders, Ace Therapeutics maintains transgenic and knockout mouse models for sickle cell disease, α- and β-thalassemia, G6PD deficiency, and hereditary spherocytosis. Researchers investigating bone marrow failure can access radiation or cyclophosphamide-induced myelosuppression rodents, immune-mediated aplastic anemia lymphocyte transfer models, and FANCA-knockout Fanconi anemia lines.
In addition to in vivo models, the company's preclinical hematology CRO services deliver cutting-edge in vitro modeling platforms, including biomimetic 3D hematopoietic culture systems that reconstruct bone marrow niche microenvironments, patient-specific iPSC-derived hematopoietic disease lines, and functional assays using primary human CD34+ hematopoietic stem and progenitor cells sourced from bone marrow, cord blood, and mobilized peripheral blood.
Beyond model development, the services extend across the full drug development lifecycle, from target identification and CRISPR-based validation to specialized PK/PD profiling tailored to blood disorder therapeutics. Hematology-focused safety pharmacology and toxicology assessments evaluate candidate treatments for impacts on hematopoiesis, clotting function, endothelial integrity, and organ toxicity in blood-rich tissues such as the spleen and bone marrow. Specialized technical support is available for all therapeutic modalities, including small-molecule iron chelators, JAK inhibitors, monoclonal antibodies, LNPs delivering RNA therapeutics, AAV/lentiviral gene vectors, and engineered cell therapies for inherited hemoglobinopathies and bleeding disorders.
All research workflows adhere to standardized operating procedures with rigorous quality control to ensure reproducible, regulatory-ready data. Clients can collaborate with Ace Therapeutics to design customized study projects, including custom CRISPR-edited animal lines, humanized hematopoietic models, and niche-focused in vitro co-culture systems for rare hematological conditions.
